IT201600128713A1 - Composizione nel trattamento dell'anemia infiammatoria o da flogosi da malattia cronica - Google Patents

Composizione nel trattamento dell'anemia infiammatoria o da flogosi da malattia cronica

Info

Publication number
IT201600128713A1
IT201600128713A1 IT102016000128713A IT201600128713A IT201600128713A1 IT 201600128713 A1 IT201600128713 A1 IT 201600128713A1 IT 102016000128713 A IT102016000128713 A IT 102016000128713A IT 201600128713 A IT201600128713 A IT 201600128713A IT 201600128713 A1 IT201600128713 A1 IT 201600128713A1
Authority
IT
Italy
Prior art keywords
flogosis
treatment
composition
chronic disease
inflammatory anemia
Prior art date
Application number
IT102016000128713A
Other languages
English (en)
Inventor
Paolo Frioni
Stefano Sugamele
Original Assignee
Frima Res Srls
Paolo Frioni
Stefano Sugamele
Bonomini Mario
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frima Res Srls, Paolo Frioni, Stefano Sugamele, Bonomini Mario filed Critical Frima Res Srls
Priority to IT102016000128713A priority Critical patent/IT201600128713A1/it
Publication of IT201600128713A1 publication Critical patent/IT201600128713A1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
IT102016000128713A 2016-12-20 2016-12-20 Composizione nel trattamento dell'anemia infiammatoria o da flogosi da malattia cronica IT201600128713A1 (it)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IT102016000128713A IT201600128713A1 (it) 2016-12-20 2016-12-20 Composizione nel trattamento dell'anemia infiammatoria o da flogosi da malattia cronica

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102016000128713A IT201600128713A1 (it) 2016-12-20 2016-12-20 Composizione nel trattamento dell'anemia infiammatoria o da flogosi da malattia cronica

Publications (1)

Publication Number Publication Date
IT201600128713A1 true IT201600128713A1 (it) 2018-06-20

Family

ID=58670161

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102016000128713A IT201600128713A1 (it) 2016-12-20 2016-12-20 Composizione nel trattamento dell'anemia infiammatoria o da flogosi da malattia cronica

Country Status (1)

Country Link
IT (1) IT201600128713A1 (it)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005068060A (ja) * 2003-08-22 2005-03-17 Nrl Pharma Inc ラクトフェリンを含有する医薬組成物ならびに加工食品の製造法
WO2008079030A1 (en) * 2006-12-22 2008-07-03 Fonterra Co-Operative Group Limited Methods of immune or haematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer
WO2008140335A2 (en) * 2007-05-14 2008-11-20 Fonterra Co-Operative Group Limited Methods of immune or hematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer, cancer symptoms, or the symptoms of cancer treatments
WO2011150395A2 (en) * 2010-05-28 2011-12-01 Bmg Hematology Llc Nutrient compositions
WO2012091945A1 (en) * 2010-12-29 2012-07-05 Mead Johnson Nutrition Company Use of nutritional compositions including lactoferrin in supporting resistance to diseases and conditions
EP2653040A1 (en) * 2012-04-19 2013-10-23 Dicofarm Spa Food based on donkey fortified milk for preterm infants and/or term infants with allergy or intollerance to cow's milk proteins and method of preparation thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005068060A (ja) * 2003-08-22 2005-03-17 Nrl Pharma Inc ラクトフェリンを含有する医薬組成物ならびに加工食品の製造法
WO2008079030A1 (en) * 2006-12-22 2008-07-03 Fonterra Co-Operative Group Limited Methods of immune or haematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer
WO2008140335A2 (en) * 2007-05-14 2008-11-20 Fonterra Co-Operative Group Limited Methods of immune or hematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer, cancer symptoms, or the symptoms of cancer treatments
WO2011150395A2 (en) * 2010-05-28 2011-12-01 Bmg Hematology Llc Nutrient compositions
WO2012091945A1 (en) * 2010-12-29 2012-07-05 Mead Johnson Nutrition Company Use of nutritional compositions including lactoferrin in supporting resistance to diseases and conditions
EP2653040A1 (en) * 2012-04-19 2013-10-23 Dicofarm Spa Food based on donkey fortified milk for preterm infants and/or term infants with allergy or intollerance to cow's milk proteins and method of preparation thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALY ESMAT ET AL: "Supplementation of infant formulas with recombinant human lactoferrin and/or galactooligosaccharides increases iron bioaccessibility as measured by ferritin formed in Caco-2 cell model", FOOD RESEARCH INTERNATIONAL, vol. 89, 24 August 2016 (2016-08-24), pages 1048 - 1055, XP029816281, ISSN: 0963-9969, DOI: 10.1016/J.FOODRES.2016.08.030 *
D Y MASON: "Intracellular lysozyme and lactoferrin in myeloproliferative disorders.", JOURNAL OF CLINICAL PATHOLOGY, vol. 30, no. 6, 1 June 1977 (1977-06-01), GB, pages 541 - 546, XP055396227, ISSN: 0021-9746, DOI: 10.1136/jcp.30.6.541 *

Similar Documents

Publication Publication Date Title
MA45192A (fr) Traitement d'association
MA42950A (fr) Administration d'agents de potentialisation de cftr modifiés au deutérium
MA42819A (fr) Procédés pour le traitement d'infections virales à arenaviridae et coronaviridae
MA46427A (fr) Compositions d'oligonucléotides et procédés associés
MA44486A (fr) Procédés d'intervention précoce pour prévenir ou atténuer la toxicité
DK3529248T3 (da) Farmaceutiske sammensætninger
MA47719A (fr) Esketamine pour le traitement de la dépression
MA55629A (fr) Compositions d'anticorps pour le traitement de tumeurs
JP2018533683A5 (it)
MA41794A (fr) Agents thérapeutiques modifiés et compositions associées
DK3412660T3 (da) Sulfonamidderivat og farmaceutisk sammensætning indeholdende samme
DK3532029T3 (da) Flydende farmaceutisk sammensætning
MA46621A (fr) Traitements combinés comprenant l'administration d'imidazopyrazinones
DK2945642T3 (da) Faktor 1 protein til anvendelse i behandling eller forebyggelse af sygdomme
MA43825A (fr) Schémas posologiques pour le traitement d'infections fongiques
IT201600121601A1 (it) Composizione orale per il trattamento del reflusso gastroesofageo e del reflusso laringo-faringeo
MA45552A (fr) Compositions destinées au traitement de l'amylose
ITUA20162575A1 (it) Composizione farmaceutica o nutraceutica per l’uso nel trattamento della sindrome dell’ovaio policistico o di malattie o disturbi correlati ad essa
MA49837A (fr) Compositions pharmaceutiques
DK3583943T3 (da) Farmaceutisk sammensætning
FR3022139B1 (fr) Nouvelles compositions pour le traitement des rougeurs cutanees et de la rosacee
MA45845A (fr) Traitement d'association pour cancers hématologiques
IT201600081379A1 (it) Composizione farmaceutica per uso nel trattamento delle patologie prostatiche.
MA50766A (fr) Composition antimicrobienne à effet renforcé pour le traitement antimicrobien de biofilms
IT201600130012A1 (it) Composizione per uso nel trattamento di disturbi dell'apparato uro-genitale